Press Releases Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
1.06 ^USD	+2.91%		+0.95%	+0.95%

04-01	Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-26	Transcript : Quince Therapeutics, Inc. - Special Call

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results	04-01	BU
Quince Therapeutics Launches Scientific Advisory Board	02-22	BU
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors	02-15	BU
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	02-07	BU
Quince Therapeutics to Participate at Investor Events in January 2024	01-04	BU
Quince Therapeutics : Investor Presentation – November 2023	11-06	PU
Quince Therapeutics Completes Acquisition of EryDel S.p.A.	23-10-23	BU
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia	23-09-28	BU
Quince Therapeutics Appoints Dr. Charles S. Ryan as President	23-09-06	BU
Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023	23-08-10	BU
Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity	23-07-24	BU
Quince Therapeutics : to Acquire EryDel Presentation	23-07-24	PU
QUINCE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	23-05-25	AQ
Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital	23-04-11	BU
Quince Therapeutics Engages MTS Health Partners as Independent Financial Advisor	23-04-06	BU
QUINCE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	23-04-05	AQ
Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan	23-04-05	BU
QUINCE THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	23-03-28	AQ
Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital	23-03-22	BU
QUINCE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Press Releases

Filters